VTGN · XBRL financial data
Vistagen Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (VTGN's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | †Mar 31, 2023 | †Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | (0) | — | — | — |
| Research and development | 12 | 35 | 44 | 20 | 39 | 55 |
| General and administrative | 7 | 13 | 15 | 14 | 17 | 18 |
| Total operating expenses | 19 | 49 | 59 | 34 | 56 | 73 |
| Operating income (loss) | (18) | (48) | (59) | (33) | (56) | (72) |
| Other income (expense) | 0 | 0 | — | — | — | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (18) | (48) | (59) | (29) | (51) | (70) |
| Earnings per share, basic‡ USD per share | (0.02) | (0.01) | (0.28) | (1.52) | (1.67) | (1.83) |
| Earnings per share, diluted USD per share | — | — | (8.51) | (1.52) | (1.67) | (1.83) |
| Weighted average shares, basic‡ millions of shares | 2,587 | 5,945 | 209 | 19 | 31 | 38 |
| Weighted average shares, diluted millions of shares | — | — | 7 | 19 | 31 | 38 |
- ‡ Per-share figures and share counts are adjusted for the 30.030030030030026-for-1 stock split (June 2023); filings made before it reported them unadjusted.
- † Share count changed about 1/26 in the period ending 2023-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (VTGN's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | †Mar 31, 2023 | †Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 103 | 68 | 17 | 119 | 67 | 31 |
| Marketable securities | — | — | — | 0 | 13 | 15 |
| Prepaid and other current assets | 1 | 3 | 1 | 1 | 2 | 2 |
| Total current assets | 104 | 71 | 18 | 121 | 82 | 47 |
| Property and equipment, net | 0 | 0 | 1 | 0 | 0 | 0 |
| Right-of-use asset | 3 | 3 | 2 | 2 | 1 | 1 |
| Total assets | 108 | 75 | 21 | 124 | 84 | 49 |
| Accounts payable | 1 | 3 | 2 | 2 | 1 | 2 |
| Accrued liabilities | 2 | 1 | 1 | 2 | 9 | 9 |
| Total current liabilities | 4 | 6 | 5 | 5 | 13 | 13 |
| Lease liability, non-current | 3 | 3 | 2 | 2 | 1 | 0 |
| Total liabilities | 16 | 10 | 9 | 9 | 14 | 13 |
| Accumulated deficit | (220) | (268) | (327) | (356) | (408) | (477) |
| Total stockholders' equity | 92 | 65 | 12 | 114 | 70 | 36 |
| Total liabilities and equity | 108 | 75 | 21 | 124 | 84 | 49 |
| Common shares outstanding (cover page)‡ millions of shares | 5,747 | 6,205 | 236 | 27 | 29 | 41 |
- ‡ Per-share figures and share counts are adjusted for the 30.030030030030026-for-1 stock split (June 2023); filings made before it reported them unadjusted.
- † Share count changed about 1/26 in the period ending 2023-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (VTGN's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | †Mar 31, 2023 | †Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (18) | (48) | (59) | (29) | (51) | (70) |
| Stock-based compensation | 2 | 3 | 3 | 2 | 4 | 4 |
| Depreciation and amortization | 0 | — | 0 | 0 | 0 | 0 |
| Net cash from operating activities | (12) | (45) | (50) | (26) | (42) | (66) |
| Purchases of property and equipment | 0 | 0 | — | — | — | — |
| Net cash from investing activities | (0) | (0) | (1) | (0) | (13) | (1) |
| Proceeds from issuing common stock | 13 | — | — | — | — | — |
| Proceeds from issuing equity | 3 | — | 0 | 93 | 0 | 0 |
| Net cash from financing activities | 114 | 10 | (1) | 128 | 3 | 31 |
| Net change in cash | 102 | (35) | (51) | 103 | (52) | (36) |
- † Share count changed about 1/26 in the period ending 2023-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Vistagen Therapeutics | 17 | not reported | (15) | 44.4M | 2.2 quarters | 10-QJun 30, 2026 |
| Agenus | 19 | 35 | (31)* | 45.0M | 0.6 quarters | 10-QJun 30, 2026 |
| Voyager Therapeutics | 36 | 3.2 | (26)* | 61.6M | 4.5 quarters | 10-QJun 30, 2026 |
| Eledon Pharmaceuticals | 6.8 | not reported | (23)* | 81.3M | 3.9 quarters | 10-QJun 30, 2026 |
| Puma Biotechnology | 37 | 57 | 1.6* | 51.6M | — | 10-QJun 30, 2026 |
| Neurogene | 112 | not reported | (24)* | 20.0M | 9.5 quarters | 10-QJun 30, 2026 |
| Skye Bioscience | 8.1 | not reported | (7.1)* | 35.4M | 1.4 quarters | 10-QJun 30, 2026 |
| Aclaris Therapeutics | 19 | 1.6 | (20)* | 147.2M | 4.6 quarters | 10-QJun 30, 2026 |
| Alpha Cognition | 41 | 6.1 | (6.9)* | 21.8M | 6.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.